The clinical effect of alteplase thrombolysis combined with butylphthalide on patients with acute cerebral infarction

doi:10.11817/j.issn.1673-9248.2020.03.007

Abstract

Abstract:

Objective

To analyze the clinical effect of alteplase intravenous thrombolysis combined with butylphthalide injection on patients with acute cerebral infarction.

Methods

96 acute cerebral infarction patients admitted to Beijing Mentougou District Hospital from October 2016 to October 2019 were divided into the control group (n=54) and the observation group (n=42). The control group was treated with alteplase alone, and the observation group was treated with alteplase combined with butylphthalide injection for 10-14 days. Clinical efficacy was assessed by NIHSS score immediately after thrombolysis, 24 hours after thrombolysis, and at discharge, and then were compared by t-test. The total effectivity and 90-day good prognosis (mRS ≤1 score) after thrombolysis were compared by χ²-test.

Results

There was no statistical difference in NIHSS score immediately after thrombolysis between two groups (P>0.05). NIHSS scores at 24 hours after thrombolysis and at discharge in the observation group significantly decreased than those in the control group [(5.65±4.06) vs (8.23±6.55), t=-2.239, P=0.027; (3.97±2.82) vs (6.36±4.28), t=3.127, P=0.002]. The total effectivity and 90-day good prognosis rate of the observation group were higher than those of the control group [95.24% vs 77.78%, χ²=5.782， P=0.016; 66.67% vs 40.74%, χ²=6.363， P=0.012].

Conclusion

Compared with only intravenous thrombolysis, Alteplase intravenous thrombolysis combined with butylphthalide injection can further improve the prognosis and reduce the disability in patients with acute cerebral infarction.

Key words: Cerebral infarction， acute, Intravenous thrombolysis, Butylphthalide

Qiang An, Caihong Gao. The clinical effect of alteplase thrombolysis combined with butylphthalide on patients with acute cerebral infarction[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2020, 14(03): 155-158.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnxgbzz.cma-cmc.com.cn/EN/10.11817/j.issn.1673-9248.2020.03.007

https://zhnxgbzz.cma-cmc.com.cn/EN/Y2020/V14/I03/155

Figures/Tables 3

References 16

1	Wenzhi Wang, Bin Jiang, Haixin Sun, et al. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults [J]. Circulation, 2017, 135(08): 759-771.
2	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018 [J]. 中华神经科杂志, 2018, 51(09): 666-682.
3	杨寓玲, 廖晓凌, 玉春娟, 等. 早期神经功能改善对缺血性卒中患者静脉溶栓后的预测作用 [J]. 中国卒中杂志, 2016, 11(04): 277-282.
4	Bang OY, Goyal M, Liebeskind DS. Collateral Circulation inIschemic Stroke: Assessment Tools and Therapeutic Strategies [J]. Stroke, 2015, 46(01): 3302-3309.
5	Zhang L, Lü L, Chan WM, et al. Effects of DL-3-n-butylphthalide on vascular dementia and angiogenesis [J]. Neurochem Res, 2012, 37(05): 911-919.
6	Campbell BC, Donnan GA, Davis SM. Vessel occlusion, penumbra, and reperfusion - translating theory to practice [J]. Front Neurol, 2014, 05: 194.
7	Manning NW, Campbell BC, Oxley TJ, et al. Acute ischemic stroke: time, penumbra, and reperfusion [J]. Stroke, 2014, 45(02): 640-644.
8	Heiss WD. The concept of the penumbra: can it be translated to stroke management? [J]. Int J Stroke, 2010, 05(04): 290-295.
9	黄石, 周峰, 张颖冬. 替罗非班在急性缺血性卒中中的研究进展 [J]. 中国脑血管病杂志, 2018, 15(11): 601-606.
10	Winship IR, Armitage GA, Ramakrishnan G, et al. Augmenting collateral blood flow during ischemic stroke via transient aortic occlusion [J]. J Cereb Blood Flow Metab, 2014, 34(01): 61-71.
11	Xi Cheng, Huibin Wang, Chang Liu, et al. Dl-3-n-butylphthalide promotes remyelination process in cerebral white matter in rats subjected to ischemic stroke [J]. Brain Res, 2019, 1717: 167-175.
12	胡火有, 肖小华, 雷志浩. 阿替普酶静脉溶栓联合丁苯酞治疗超早期脑梗死的疗效观察 [J]. 现代诊断与治疗, 2018, 29(11): 1698-1700.
13	侯园园, 梁志刚, 孙旭文, 等. 丁苯酞联合阿替普酶治疗缺血性卒中临床疗效的观察性研究 [J]. 中国卒中杂志, 2019, 14(03): 225-230.
14	李彬, 罗仕俊. 丁苯酞联合阿替普酶静脉溶栓治疗急性脑梗死的临床疗效分析 [J]. 吉林医学, 2020, 41(02): 337-338.
15	Xi-Qian Chen, Ke Qiu, Hui Liu, et al. Application and prospects of butylphthalide for the treatment of neurologic diseases [J]. Chin Med J (Engl), 2019, 132(12): 1467-1477.
16	Chuan Qin, Panting Zhou, Liping Wang, et al. Dl-3-N-butylphthalide attenuates ischemic reperfusion injury by improving the function of cerebral artery and circulation [J]. J Cereb Blood Flow Metab, 2019, 39(10): 2011-2021.

组别	例数	年龄（岁，）	男性[例（%）]	吸烟[例（%）]	高血压[例（%）]	糖尿病[例（%）]	心房颤动[例（%）]	单纯后循环梗死[例（%）]	治疗时长（d，）	入院NIHSS评分（分，）
联合治疗组	42	68.26±12.18	26（61.90）	24（57.14）	29（69.05）	11（26.19）	5（11.90）	12（28.57）	12.01±3.24	13.85±7.32
单独治疗组	54	70.02±15.26	32（59.26）	28（51.85）	38（70.37）	17（31.48）	7（12.96）	18（33.33）	10.82±2.96	12.26±10.06
统计值		t=-0.611	χ²=0.069	χ²=0.266	χ²=0.020	χ²=0.320	χ²=0.024	χ²=0.249	t=1.854	t=0.862
P值		0.543	0.793	0.606	0.889	0.572	0.876	0.618	0.067	0.391

组别	例数	年龄（岁，）	男性[例（%）]	吸烟[例（%）]	高血压[例（%）]	糖尿病[例（%）]	心房颤动[例（%）]	单纯后循环梗死[例（%）]	治疗时长（d，）	入院NIHSS评分（分，）
联合治疗组	42	68.26±12.18	26（61.90）	24（57.14）	29（69.05）	11（26.19）	5（11.90）	12（28.57）	12.01±3.24	13.85±7.32
单独治疗组	54	70.02±15.26	32（59.26）	28（51.85）	38（70.37）	17（31.48）	7（12.96）	18（33.33）	10.82±2.96	12.26±10.06
统计值		t=-0.611	χ²=0.069	χ²=0.266	χ²=0.020	χ²=0.320	χ²=0.024	χ²=0.249	t=1.854	t=0.862
P值		0.543	0.793	0.606	0.889	0.572	0.876	0.618	0.067	0.391

组别	例数	溶栓后即刻NIHSS评分	溶栓后24 hNIHSS评分	出院时NIHSS评分
联合治疗组	42	10.98±5.22	5.65±4.06	3.97±2.82
单独治疗组	54	9.12±4.67	8.23±6.55	6.36±4.28
t值		1.838	-2.239	-3.127
P值		0.069	0.027	0.002

组别	例数	溶栓后即刻NIHSS评分	溶栓后24 hNIHSS评分	出院时NIHSS评分
联合治疗组	42	10.98±5.22	5.65±4.06	3.97±2.82
单独治疗组	54	9.12±4.67	8.23±6.55	6.36±4.28
t值		1.838	-2.239	-3.127
P值		0.069	0.027	0.002

组别	例数	显效[例（%）]	有效[例（%）]	无效[例（%）]	总有效率[例（%）]	mRS评分0~1分[例（%）]
联合治疗组	42	11（26.19）	29（69.05）	2（4.76）	40（95.24）	28（66.67）
单独治疗组	54	12（22.22）	30（55.56）	12（22.22）	42（77.78）	22（40.74）
χ²值		0.204	1.816	5.782	5.782	6.363
P值		0.651	0.178	0.016	0.016	0.012

Please choose a citation manager

Content to export